114 related articles for article (PubMed ID: 21555404)
21. Drug-induced long QT syndrome and torsade de pointes.
Morissette P; Hreiche R; Turgeon J
Can J Cardiol; 2005 Aug; 21(10):857-64. PubMed ID: 16107909
[TBL] [Abstract][Full Text] [Related]
22. Quetiapine and the need for a thorough QT/QTc study.
Hasnain M; Vieweg WV; Howland RH; Kogut C; Breden Crouse EL; Koneru JN; Hancox JC; Digby GC; Baranchuk A; Deshmukh A; Pandurangi AK
J Clin Psychopharmacol; 2014 Feb; 34(1):3-6. PubMed ID: 24346758
[No Abstract] [Full Text] [Related]
23. [Current classification of anti-arrhythmia agents].
Weirich J; Wenzel W
Z Kardiol; 2000; 89 Suppl 3():62-7. PubMed ID: 10810787
[TBL] [Abstract][Full Text] [Related]
24. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
Drici MD; Clément N
Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
[TBL] [Abstract][Full Text] [Related]
25. Potassium channel blockade amplifies cardiac instability numerical studies of torsades de pointes.
Starmer CF; Reddy MR; Namasivayam A; Singh M
Indian J Physiol Pharmacol; 1994 Oct; 38(4):259-66. PubMed ID: 7883289
[TBL] [Abstract][Full Text] [Related]
26. A step towards characterisation of electrophysiological profile of torsadogenic drugs.
Champeroux P; Ouillé A; Martel E; Fowler JS; Maurin A; Richard S; Le Guennec JY
J Pharmacol Toxicol Methods; 2011; 63(3):269-78. PubMed ID: 21224008
[TBL] [Abstract][Full Text] [Related]
27. Serious QT interval prolongation with ranolazine and amiodarone.
Tarapués M; Cereza G; Arellano AL; Montané E; Figueras A
Int J Cardiol; 2014 Mar; 172(1):e60-1. PubMed ID: 24424337
[No Abstract] [Full Text] [Related]
28. Sevoflurane and QTc Prolongation: An Interesting Observation, or a Clinically Significant Finding?
Scuderi PE
Anesthesiology; 2010 Oct; 113(4):772-5. PubMed ID: 20808205
[No Abstract] [Full Text] [Related]
29. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR
J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331
[TBL] [Abstract][Full Text] [Related]
30. [Polymorph ventricular tachycardia with torsades de pointes caused by administration of terodiline (Mictrol)].
van der Klauw MM; van Rey FJ; Stricker BH
Ned Tijdschr Geneeskd; 1992 Jan; 136(2):91-3. PubMed ID: 1370730
[TBL] [Abstract][Full Text] [Related]
31. Models of torsades de pointes: effects of FPL64176, DPI201106, dofetilide, and chromanol 293B in isolated rabbit and guinea pig hearts.
Cheng HC; Incardona J
J Pharmacol Toxicol Methods; 2009; 60(2):174-84. PubMed ID: 19524054
[TBL] [Abstract][Full Text] [Related]
32. [Ventricular tachycardia caused by terodiline].
Kristensen D; Andersen M
Ugeskr Laeger; 1992 Apr; 154(16):1126. PubMed ID: 1523728
[No Abstract] [Full Text] [Related]
33. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
Qu Y; Vargas HM
Toxicol Sci; 2015 Sep; 147(1):286-95. PubMed ID: 26117837
[TBL] [Abstract][Full Text] [Related]
34. Antidepressants: their effects on cardiac channels, QT prolongation and Torsade de Pointes.
Sala M; Coppa F; Cappucciati C; Brambilla P; d'Allio G; Caverzasi E; Barale F; De Ferrari GM
Curr Opin Investig Drugs; 2006 Mar; 7(3):256-63. PubMed ID: 16555686
[TBL] [Abstract][Full Text] [Related]
35. Effects of common antitussive drugs on the hERG potassium channel current.
Deisemann H; Ahrens N; Schlobohm I; Kirchhoff C; Netzer R; Möller C
J Cardiovasc Pharmacol; 2008 Dec; 52(6):494-9. PubMed ID: 19034038
[TBL] [Abstract][Full Text] [Related]
36. [Mictrol is withdrawn after adverse cardiac effects. An account of Swedish cases].
Lakartidningen; 1991 Oct; 88(42):3488. PubMed ID: 1943354
[No Abstract] [Full Text] [Related]
37. Pharmacological targeting of ion channels for cancer therapy: In vivo evidences.
Leanza L; Managò A; Zoratti M; Gulbins E; Szabo I
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt B):1385-97. PubMed ID: 26658642
[TBL] [Abstract][Full Text] [Related]
38. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs.
Singh BN; Wadhani N
J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S85-97. PubMed ID: 15378133
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers.
Huo J; Kamalakar A; Yang X; Word B; Stockbridge N; Lyn-Cook B; Pang L
Toxicol Sci; 2017 Mar; 156(1):25-38. PubMed ID: 28031415
[TBL] [Abstract][Full Text] [Related]
40. An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel.
Crumb WJ; Vicente J; Johannesen L; Strauss DG
J Pharmacol Toxicol Methods; 2016; 81():251-62. PubMed ID: 27060526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
